[go: up one dir, main page]

AU5047393A - Intermediates useful in the preparation of N-sulfonyl-indoline derivatives - Google Patents

Intermediates useful in the preparation of N-sulfonyl-indoline derivatives

Info

Publication number
AU5047393A
AU5047393A AU50473/93A AU5047393A AU5047393A AU 5047393 A AU5047393 A AU 5047393A AU 50473/93 A AU50473/93 A AU 50473/93A AU 5047393 A AU5047393 A AU 5047393A AU 5047393 A AU5047393 A AU 5047393A
Authority
AU
Australia
Prior art keywords
denotes
alkyl
group
trifluoromethyl
naphthyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU50473/93A
Other versions
AU664491B2 (en
Inventor
Dino Nisato
Claude Plouzane
Claudine Serradeil-Le Gal
Jean Wagnon
Paul De Cointet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU5047393A publication Critical patent/AU5047393A/en
Assigned to ELF SANOFI reassignment ELF SANOFI Amend patent request/document other than specification (104) Assignors: SANOFI
Application granted granted Critical
Publication of AU664491B2 publication Critical patent/AU664491B2/en
Assigned to SANOFI-SYNTHELABO reassignment SANOFI-SYNTHELABO Request to Amend Deed and Register Assignors: ELF SANOFI
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds of formula: <IMAGE> in which - R1 denotes a halogen atom, a C1-C4 alkyl or alkoxy, a hydroxyl or a benzyloxy, cyano, trifluoromethyl, nitro or amino group; - R2 denotes a C1-C6 alkyl, a C3-C7 cycloalkyl, a C5-C7 cycloalkene, a phenyl, unsubstituted or mono- or polysubstituted by a C1-C4 alkyl or alkoxy, a halogen or a trifluoromethyl, nitro or amino group; - R3 denotes a hydrogen atom or a C1-C4 alkyl; - R4 denotes a carboxyl group, a C1-C6 alkoxycarbonyl group, a benzyloxycarbonyl group or a carboxamide group of formula CONR6R7; - R5 denotes a C1-C4 alkyl, 1-naphthyl, 2-naphthyl, 5-dimethylamino-1-naphthyl, phenyl, unsubstituted or substituted by one or more substituents chosen from a halogen, a C1-C4 alkyl, a trifluoromethyl, nitro, amino group free or substituted by one or 2 C1-C4 alkyls, a hydroxyl, a C1-C4 alkoxy, a C1-C4 alkenoxy, a C1-C4 alkylthio or a trifluoromethoxy, benzyloxy, cyano, carboxyl, C1-C4 alkoxycarbonyl, carbamoyl or C1-C4 alkylamido group or, when m = 0, R5 may denote a group: <IMAGE> - each of R6 and R7 independently denotes hydrogen, a C1-C6 alkyl, a phenylalkyl in which the alkyl is C1-C4 or R6 and R7 together form a -(CH2)p- group; - n denotes 0, 1 or 2; - m denotes 0, 1 or 2; - p denotes 4, 5 or 6; and their optional salts. These compounds have an affinity for the vasopressin and ocytocin receptors.
AU50473/93A 1990-07-31 1993-11-05 Intermediates useful in the preparation of N-sulfonyl-indoline derivatives Ceased AU664491B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9009778A FR2665441B1 (en) 1990-07-31 1990-07-31 N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR9009778 1990-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU81478/91A Division AU645585B2 (en) 1990-07-31 1991-07-31 N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present

Publications (2)

Publication Number Publication Date
AU5047393A true AU5047393A (en) 1994-01-13
AU664491B2 AU664491B2 (en) 1995-11-16

Family

ID=9399281

Family Applications (2)

Application Number Title Priority Date Filing Date
AU81478/91A Ceased AU645585B2 (en) 1990-07-31 1991-07-31 N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
AU50473/93A Ceased AU664491B2 (en) 1990-07-31 1993-11-05 Intermediates useful in the preparation of N-sulfonyl-indoline derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU81478/91A Ceased AU645585B2 (en) 1990-07-31 1991-07-31 N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present

Country Status (17)

Country Link
EP (1) EP0469984B1 (en)
JP (1) JP3195381B2 (en)
KR (1) KR100211434B1 (en)
AT (1) ATE129236T1 (en)
AU (2) AU645585B2 (en)
CA (1) CA2048139C (en)
DE (1) DE69113911T2 (en)
ES (1) ES2080922T3 (en)
FI (1) FI97224C (en)
FR (1) FR2665441B1 (en)
HU (1) HU220765B1 (en)
IE (1) IE73452B1 (en)
IL (2) IL99012A (en)
NO (1) NO175254C (en)
NZ (1) NZ239182A (en)
PT (1) PT98476B (en)
ZA (1) ZA916031B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU691223B2 (en) * 1991-08-02 1998-05-14 Sanofi-Synthelabo Intermediates useful in the preparation of indoline derivatives carrying an amide functional group

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US5481005A (en) * 1990-07-31 1996-01-02 Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
CA2166975C (en) * 1993-07-16 2005-04-05 Mark G. Bock Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
EP0708765A4 (en) * 1993-07-16 1996-06-26 Merck & Co Inc PIPERAZINYLCAMPHER DERIVATIVES SUBSTITUTED AS OXYTOCIN ANTAGONISTS
FR2708608B1 (en) * 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
FR2708606B1 (en) * 1993-07-30 1995-10-27 Sanofi Sa N-phenylalkylindol-2-one derivatives, their preparation, pharmaceutical compositions containing them.
FR2714378B1 (en) * 1993-12-24 1996-03-15 Sanofi Sa Indol-2-one derivatives substituted in 3 with a nitrogen group, their preparation, pharmaceutical compositions containing them.
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
ATE464292T1 (en) 2000-10-17 2010-04-15 Merck Serono Sa PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0116594D0 (en) 2001-07-06 2001-08-29 Cancer Res Ventures Ltd Therapeutic compounds
CA2469042A1 (en) 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles as oxytocin antagonists
CA2784937A1 (en) * 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
JP4465281B2 (en) * 2002-12-20 2010-05-19 キャンサー・リサーチ・テクノロジー・リミテッド 4- (1- (sulfonyl) -1H-indol-2-yl) -4- (hydroxy) -cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents
FR2853650B1 (en) * 2003-04-10 2006-07-07 Merck Sante Sas AMINE DEDOUBLING PROCESS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULINO-RESISTANCE SYNDROME
FR2880023B1 (en) 2004-12-23 2007-02-23 Sanofi Aventis Sa N - [(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE
FR2927625B1 (en) 2008-02-19 2010-03-12 Sanofi Aventis NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2930249B1 (en) 2008-04-21 2010-05-14 Sanofi Aventis NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (en) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 Macrocyclic orexin agonists
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (en) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl derivatives, processes for their preparation, and their use as medicaments
GB8820129D0 (en) * 1988-08-24 1988-09-28 Schering Agrochemicals Ltd Fungicides
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU691223B2 (en) * 1991-08-02 1998-05-14 Sanofi-Synthelabo Intermediates useful in the preparation of indoline derivatives carrying an amide functional group

Also Published As

Publication number Publication date
CA2048139A1 (en) 1992-02-01
PT98476A (en) 1992-05-29
FI913614L (en) 1992-02-01
ES2080922T3 (en) 1996-02-16
FR2665441B1 (en) 1992-12-04
ZA916031B (en) 1992-04-29
FI97224B (en) 1996-07-31
DE69113911T2 (en) 1996-03-28
EP0469984B1 (en) 1995-10-18
IE73452B1 (en) 1997-06-04
IL99012A (en) 1996-07-23
NO175254C (en) 1994-09-21
NZ239182A (en) 1995-07-26
FR2665441A1 (en) 1992-02-07
EP0469984A2 (en) 1992-02-05
HU220765B1 (en) 2002-05-28
HUT59669A (en) 1992-06-29
NO175254B (en) 1994-06-13
HU912552D0 (en) 1992-01-28
JPH04234361A (en) 1992-08-24
CA2048139C (en) 2002-02-12
KR100211434B1 (en) 1999-08-02
AU8147891A (en) 1992-02-06
FI913614A0 (en) 1991-07-29
EP0469984A3 (en) 1992-03-11
NO912970D0 (en) 1991-07-30
JP3195381B2 (en) 2001-08-06
IL114934A0 (en) 1995-12-08
IE912696A1 (en) 1992-02-12
IL99012A0 (en) 1992-07-15
ATE129236T1 (en) 1995-11-15
PT98476B (en) 1997-10-31
KR920002537A (en) 1992-02-28
NO912970L (en) 1992-02-03
DE69113911D1 (en) 1995-11-23
FI97224C (en) 1996-11-11
AU645585B2 (en) 1994-01-20
AU664491B2 (en) 1995-11-16

Similar Documents

Publication Publication Date Title
AU5047393A (en) Intermediates useful in the preparation of N-sulfonyl-indoline derivatives
IE801713L (en) N-(3-mercapto-2-alkyl-1-oxopropyl)-2,¹3-dihydro-1h-indole-2-carboxylic acids
AU3956593A (en) Perhydroisoindole derivatives as P substance antagonists
AU1070895A (en) Indole-derived arylpiperazines as ligands for 5HT1-like receptors 5HT1B and 5HT1D
DE69728544D1 (en) TOTAL SYNTHESIS OF ACYL FULVENES WITH ANTITUARY EFFECT
ATE168672T1 (en) INDOLE-PIPERAZINE DERIVATIVES AS SELECTIVE LIGANDS OF THE 5HT1D AND 5HT1B RECEPTORS USABLE AS MEDICINAL PRODUCTS
ES2138623T3 (en) PLEUROMUTILINE DERIVATIVES.
CA2209422A1 (en) 4-amino-3-acylnaphthyridine derivatives
TW342389B (en) Arylalkyl-thiadiazinones
DK0646110T3 (en) N-substituted 3-azabicyclo (3.2.0) heptane derivatives as neuroleptics
DK0689534T3 (en) Amide derivatives such as 5-HT1A ligands
PL312582A1 (en) Use of cephem derivatives as antimetastatic means
AU5674894A (en) Azanoradamantanes
AU1960295A (en) Ocular tension depressant
AU6506894A (en) Perhydroisoindole derivatives, preparation thereof and pharmaceutical compositions containing same
AU1590595A (en) Carbamoylmethylurea derivative
ZA941334B (en) Amide derivative .
CO4920233A1 (en) GAMMA AMINOBUTY ACIDS SUBSTITUTED AS PHARMACEUTICAL AGENTS
CO4750832A1 (en) NEW QUINOLINE DERIVATIVES

Legal Events

Date Code Title Description
HB Alteration of name in register

Free format text: SANOFI-SYNTHELABO